Assess whether the primary endpoint will survive FDA scrutiny (bdb167)

SITUATION Clinical-development physician is responsible for the primary endpoint will in a 505(b)(2) program relying on literature plus a bridging study, using disproportionate reporting signal workbook as the only working extract. A CRL citing manufacturing, not efficacy is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled Pharmacovigilance process in a 505(b)(2) program relying on literature plus a bridging study, given disproportionate reporting signal workbook. 2. A CRL citing manufacturing, not efficacy is the event in disproportionate reporting signal workbook that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Disproportionate reporting signal workbook shows a one-file miss after a CRL citing manufacturing, not efficacy, not a Pharmacovigilance program failure. 4. Disproportionate reporting signal workbook cannot decide the primary endpoint will yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CRL citing manufacturing, not efficacy and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in disproportionate reporting signal workbook, then the action for clinical-development physician - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in disproportionate reporting signal workbook that a second reviewer can re-perform